In recent years, several new therapeutic strategies have been explored, the most promising being immune checkpoint inhibitors (ICIs), blocking the programmed cell death protein 1/programmed cell death1 ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4), which are currently the standard of care for many advanced solid and hematologic malignancies [5], and anti-angiogenic strategies [6,7,8]. The gene discussed is PDCD1; the disease is hematologic disorder.